UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 71

Sortiert nach

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

European journal of cancer (1990), 2011-01, Vol.47 (1), p.8-32

2011

Link zum Volltext

Verfügbarkeit prüfen

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

European journal of cancer (1990), 2007-01, Vol.43 (2), p.258-270

2007

Link zum Volltext

Verfügbarkeit prüfen

Practical guidance for the management of aromatase inhibitor-associated bone loss

Annals of oncology, 2008-08, Vol.19 (8), p.1407-1416

2008

Link zum Volltext

Verfügbarkeit prüfen

Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?

Cancer treatment reviews, 2012-10, Vol.38 (6), p.798-806

2012

Link zum Volltext

Verfügbarkeit prüfen

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis

European journal of cancer (1990), 2009-03, Vol.45 (4), p.608-617

2009

Link zum Volltext

Verfügbarkeit prüfen

F9 Adjuvant chemotherapy for elderly women with breast cancer: immediate benefit and long-term risk

Critical reviews in oncology/hematology, 2009, Vol.72 (1), p.S9-S10

Aapro, M.S

2009

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)

Annals of oncology, 2019-10, Vol.30, p.v722

2019

Link zum Volltext

Verfügbarkeit prüfen

1765P - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)

Annals of oncology, 2019-10, Vol.30, p.v722-v722

2019

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma

Annals of oncology, 2000-03, Vol.11 (3), p.301-306

2000

Link zum Volltext

Verfügbarkeit prüfen

371P Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab

Annals of oncology, 2023-10, Vol.34, p.S330-S330

2023

Link zum Volltext

Verfügbarkeit prüfen

2078P Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan

Annals of oncology, 2023-10, Vol.34, p.S1093-S1094

2023

Link zum Volltext

Verfügbarkeit prüfen

Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force

Critical reviews in oncology/hematology, 2007-04, Vol.62 (1), p.62-73

2007

Link zum Volltext

Verfügbarkeit prüfen

PCN16 Disease Burden and Treatment outcomes in Second-Line Therapy of Patients with Estrogen-Receptor Positive (ER+) Advanced Breast Cancer: A Review of the Literature

Value in health, 2011, Vol.14 (7), p.A436-A436

2011

Link zum Volltext

Verfügbarkeit prüfen

3056 POSTER Effect of Palonosetron Plus 1-day Dexamethasone (DEX) on the Prevention of Delayed Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy (MEC): a Pooled Analysis of Two Phase III Trials

European journal of cancer (1990), 2011, Vol.47, p.S239-S239

2011

Link zum Volltext

Verfügbarkeit prüfen

Aprepitant: drug–drug interactions in perspective

Annals of oncology, 2010-12, Vol.21 (12), p.2316-2323

2010

Link zum Volltext

Verfügbarkeit prüfen

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

Annals of oncology, 2011-12, Vol.22 (12), p.2546-2555

2011

Link zum Volltext

Verfügbarkeit prüfen

188P Pooled analysis of two phase II randomised studies (NorBreast-231 & TEMPO Breast) evaluating weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)

Annals of oncology, 2022-05, Vol.33, p.S214-S214

2022

Link zum Volltext

Verfügbarkeit prüfen

455P Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period

Annals of oncology, 2023-11, Vol.34, p.S1640

2023

Link zum Volltext

Verfügbarkeit prüfen

295TiP Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy

Annals of oncology, 2022-11, Vol.33, p.S1546-S1546

2022

Link zum Volltext

Verfügbarkeit prüfen

5056 POSTER Analysis of Metastatic Breast Cancer Management Across Europe -the EOS Study (European Observatory & Survey)

European journal of cancer (1990), 2011, Vol.47, p.S347-S347

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients

Annals of oncology, 2016-10, Vol.27, p.vi499-vi499

2016

Link zum Volltext

Verfügbarkeit prüfen

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

European journal of cancer (1990), 2006-10, Vol.42 (15), p.2433-2453

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Annals of oncology, 2006-09, Vol.17 (9), p.1441-1449

2006

Link zum Volltext

Verfügbarkeit prüfen

Biosimilar epoetin alfa (HX575) for the treatment of chemotherapy-induced anaemia: Development, approval and 10 years’ clinical experience

Annals of oncology, 2017-09, Vol.28, p.v560-v561

2017

Link zum Volltext

Verfügbarkeit prüfen

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer

European journal of cancer (1990), 2004-10, Vol.40 (15), p.2201-2216

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(71)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(29)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Oncology
(28)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Pharmacology. Drug Treatments
(17)
Female
(16)
Aged
(13)
Antineoplastic Agents
(11)
Hematology, Oncology And Palliative Medicine
(11)
Male
(11)
Middle Aged
(9)
Neoplasms - Drug Therapy
(9)
Tumors
(9)
Adult
(7)
Antineoplastic Agents - Adverse Effects
(7)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Breast Neoplasms - Drug Therapy
(6)
Breast Cancer
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

Practical guidance for the management of aromatase inhibitor-associated bone loss

Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis

F9 Adjuvant chemotherapy for elderly women with breast cancer: immediate benefit and long-term risk

Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)

1765P - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)

Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma

371P Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab

2078P Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan

Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force

PCN16 Disease Burden and Treatment outcomes in Second-Line Therapy of Patients with Estrogen-Receptor Positive (ER+) Advanced Breast Cancer: A Review of the Literature

3056 POSTER Effect of Palonosetron Plus 1-day Dexamethasone (DEX) on the Prevention of Delayed Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy (MEC): a Pooled Analysis of Two Phase III Trials

Aprepitant: drug–drug interactions in perspective

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

188P Pooled analysis of two phase II randomised studies (NorBreast-231 & TEMPO Breast) evaluating weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)

455P Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period

295TiP Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy

5056 POSTER Analysis of Metastatic Breast Cancer Management Across Europe -the EOS Study (European Observatory & Survey)

Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Biosimilar epoetin alfa (HX575) for the treatment of chemotherapy-induced anaemia: Development, approval and 10 years’ clinical experience

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer

Suchergebnisse filtern